Rabbit Recombinant Monoclonal GC-C antibody. Suitable for WB and reacts with Human samples.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
WB | Flow Cyt (Intra) | IP | IHC-P | ICC/IF | |
---|---|---|---|---|---|
Human | Tested | Not recommended | Not recommended | Not recommended | Not recommended |
Mouse | Not recommended | Not recommended | Not recommended | Not recommended | Not recommended |
Rat | Not recommended | Not recommended | Not recommended | Not recommended | Not recommended |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1/1000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human, Mouse, Rat | Dilution info - | Notes - |
Select an associated product type
Guanylyl cyclase that catalyzes synthesis of cyclic GMP (cGMP) from GTP (PubMed:11950846, PubMed:1718270, PubMed:22436048, PubMed:22521417, PubMed:23269669). Receptor for the E.coli heat-stable enterotoxin; E.coli enterotoxin markedly stimulates the accumulation of cGMP in mammalian cells expressing GUCY2C (PubMed:1680854, PubMed:1718270). Also activated by the endogenous peptides guanylin and uroguanylin (PubMed:8381596).
GUC2C, STAR, GUCY2C, Guanylyl cyclase C, GC-C, Heat-stable enterotoxin receptor, Intestinal guanylate cyclase, STA receptor, hSTAR
Rabbit Recombinant Monoclonal GC-C antibody. Suitable for WB and reacts with Human samples.
pH: 7.2 - 7.4
Preservative: 0.01% Sodium azide
Constituents: 59% PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
GC-C also known as guanylate cyclase C is an enzyme with mass around 120 kDa expressed mainly in the intestinal epithelium. This membrane-bound receptor plays an important role in the regulation of fluid and electrolyte balance in the intestine. GC-C gets activated by its ligands including bacterial heat-stable enterotoxins as well as endogenous peptides like guanylin and uroguanylin. Upon activation GC-C catalyzes the conversion of GTP to cGMP thereby initiating a signaling cascade that affects ion transport in intestinal cells.
GC-C is part of a signaling mechanism involved in maintaining fluid balance and gut homeostasis. The enzyme participates in the cGMP-mediated signaling pathway essential for modulating chloride and bicarbonate ion secretion leading to water loss into the intestinal lumen. GC-C does not work in isolation but cooperates with other molecules to facilitate these functions. Specifically it associates with ion transporters and channels influencing the enteric nervous system.
GC-C functions within the cGMP pathway which is critical for intestinal fluid regulation. GC-C also connects with the Wnt signaling pathway an important metabolic relay influencing cell proliferation and differentiation. By producing cGMP GC-C influences down-stream proteins such as protein kinase G (PKG) and cystic fibrosis transmembrane conductance regulator (CFTR). These proteins play pivotal roles in maintaining the physiological processes in the intestine.
GC-C relates to irritable bowel syndrome (IBS) and colorectal cancer. Overactivation of GC-C by bacterial toxins can lead to enterotoxigenic diarrhea common in IBS. Its role in colorectal cancer arises from dysregulated signaling pathways affecting cellular growth. Mutations and alterations in GC-C expression may contribute to cancer progression. Furthermore GC-C-related dysregulation can involve other proteins like E-cadherin which modulates cell adhesion in tumor pathways complicating disease dynamics.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Blocking and diluting buffer and concentration: 5% NFDM/TBST
Low expression: spleen, liver
The identity of the bands above 250 kDa is unknown.
In Western blot, Anti-GAPDH antibody [EPR16891] - Loading Control (Anti-GAPDH antibody [EPR16891] - Loading Control ab181602) staining at 1/200000 dilution.
All lanes: Western blot - Anti-GC-C antibody [EPR26427-38] (ab314309) at 1/1000 dilution
Lane 1: Human colon tissue lysate at 20 µg
Lane 2: Human colon cancer tissue lysate at 20 µg
Lane 3: Human spleen tissue lysate at 20 µg
Lane 4: Human liver tissue lysate at 20 µg
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/100000 dilution
Observed band size: 145 kDa, 155 kDa
Exposure time: 48s
Blocking and diluting buffer and concentration: 5% NFDM/TBST
GC-C is a glycoprotein of approximately 145 kDa and detected as a 130kDa band after treated with Protein Deglycosylation MIX II.
GC-C is expressed in two differentially glycosylated forms.(PMID:23269669, PMID:12950269, PMID:14748740)
The identity of the bands above 250 kDa is unknown.
The identity of the bands below 37 kDa is unknown.
In Western blot, Anti-GAPDH antibody [EPR16891] - Loading Control (Anti-GAPDH antibody [EPR16891] - Loading Control ab181602) staining at 1/200000 dilution.
All lanes: Western blot - Anti-GC-C antibody [EPR26427-38] (ab314309) at 1/1000 dilution
Lane 1: Untreated T84 (human colon epithelial cell) whole cell lysate at 15 µg
Lane 2: T84 whole cell lysate treated with Protein Deglycosylation MIX II at 15 µg
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/100000 dilution
Observed band size: 130 kDa, 145 kDa, 155 kDa
Exposure time: 48s
Blocking and diluting buffer and concentration: 5% NFDM/TBST
Negative control: HCT 116(PMID: 31996389)
GC-C is expressed in two differentially glycosylated forms.(PMID:23269669, PMID:12950269, PMID:14748740)
The identity of the bands above 250 kDa is unknown.
The identity of the bands below 37 kDa is unknown.
In Western blot, Anti-GAPDH antibody [EPR16891] - Loading Control (Anti-GAPDH antibody [EPR16891] - Loading Control ab181602) staining at 1/200000 dilution.
All lanes: Western blot - Anti-GC-C antibody [EPR26427-38] (ab314309) at 1/1000 dilution
Lane 1: T84 (human colon epithelial cell) whole cell lysate at 20 µg
Lane 2: HCT116 (human colorectal carcinoma epithelial cell) whole cell lysate at 20 µg
All lanes: Western blot - Goat Anti-Rabbit IgG H&L (HRP) (Goat Anti-Rabbit IgG H&L (HRP) ab97051) at 1/100000 dilution
Observed band size: 145 kDa, 155 kDa
Exposure time: 26s
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com